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Objectives: In patients with acute recurrent pancreatitis (ARP), pancreas divisum, and no other 
etiologic factors, endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla 
endoscopic sphincterotomy (miES) is often performed to enlarge the minor papillary orifice, based 
on limited data. The aims of this study are to describe the rationale and methodology of a sham-
controlled clinical trial designed to test the hypothesis that miES reduces the risk of acute 
pancreatitis.
Methods: The SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial is a multicenter, 
international, sham-controlled, randomized trial comparing endoscopic ultrasound + ERCP with 
miES vs. endoscopic ultrasound + sham for the management of ARP. A total of 234 consented 
patients having two or more discrete episodes of acute pancreatitis, pancreas divisum confirmed by 
magnetic resonance cholangiopancreatography, and no other clear etiology for acute pancreatitis 
will be randomized. Both cohorts will be followed for a minimum of 6 months and maximum of 
48 months.
Results: The trial is powered to detect a 33% risk reduction of acute pancreatitis frequency.
Conclusions: The SHARP trial will determine whether ERCP with miES benefits patients with 
idiopathic ARP and pancreas divisum. Trial planning has informed the importance of blinded 
outcome assessors and long-term follow-up.
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Introduction
Unlike patients with chronic pancreatitis, patients with acute recurrent pancreatitis (ARP) 
are unique in that most do not have end organ morphological and functional changes at the 
time of their clinical presentation. However, patients with ARP have a substantial (10–40%) 
risk of progressing to chronic pancreatitis and its sequelae of chronic pain, malabsorption, 
diabetes mellitus, poor quality of life, and pancreatic ductal adenocarcinoma.1–3 Treatments 
to attenuate ARP are needed.
The concept was promulgated in the 1970s that in pancreas divisum there is an anatomic 
impediment to the drainage of pancreatic exocrine secretions, resulting in an obstructive 
pancreatopathy.4 Treatment of pancreas divisum involves enlargement of the minor papillary 
orifice via minor papilla sphincterotomy, serial dilation and stent placement, or surgical 
sphincteroplasty. Endoscopic minor papilla sphincterotomy is favored over surgery and 
serial stenting because of its lower short-term morbidity and reduced need for repeated 
procedures to exchange or remove therapeutic stents, respectively; repeated stent exchanges 
confer some risk of stent-induced injury to the pancreatic duct.5
There are limited preliminary data supporting the use of endoscopic retrograde 
cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy (miES). 
Although the technique of miES has been performed for >30 years, there has been only one 
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pilot, open-label, randomized trial of 19 patients with idiopathic ARP published over 20 
years ago.6 This study compared serial dilation of the minor papillary orifice via pancreatic 
stents – a surrogate for miES – vs diagnostic ERCP. After mean follow-up of 29–32 months, 
6/9 (67%) patients who underwent sham ERCP developed at least one bout of acute 
pancreatitis as compared to 1/10 (10%, P < 0.05) that underwent serial pancreatic duct stent 
placement.
Several retrospective cohort studies also support the practice of miES for ARP in the setting 
of pancreas divisum, with approximately 70% of patients in most studies reporting a 
significant improvement in their disease course.7 While supporting the role of miES, these 
studies chose a subjective endpoint (self-perceived improvement) despite their open-label 
design and absence of a sham comparison group. The controversy is a recurrent topic at 
national meetings, and opposite positions were nicely summarized after a debate at the 2006 
meeting of the American Pancreatic Association.8 Both sides acknowledged the need for 
randomized trials, yet there has been little progress in clarifying the benefit of miES on 
idiopathic ARP with pancreas divisum over the past decade.9 Given the longstanding 
controversy, the SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) randomized 
trial is being conducted to definitely answer the question of whether miES can reduce the 
risk of acute pancreatitis by relieving the purported obstruction of pancreatic juice outflow 
caused by divisum anatomy.
MATERIALS AND METHODS
The SHARP trial is a sham-controlled, blinded outcome assessment, intention to treat, multi-
center, randomized clinical trial of ERCP with miES for the treatment of ARP with pancreas 
divisum. The trial requires 234 randomized participants during a planned enrollment period 
of approximately 3.5 years at 17 or more medical centers, with total planned study duration 
of 5 years (Fig. 1).
Trial Organization
The SHARP trial is funded by the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) and registered in http://clinicaltrials.gov (). Recognizing the effort and 
skill required to execute the various aspects of a large clinical trial, the SHARP trial has 
three principal investigators, each having a specified focus. The administrative PI (G.A.C.) 
oversees the work of the Clinical Coordinating Center and chairs the Steering, Publication 
and Ancillary Study Committees. The protocol PI (D.Y.) chairs the Executive and 
Biorepository Committees and oversees the scientific aspects related to the trial protocol. 
The Statistical and Data Coordinating Center PI (V.L.D-M.) is responsible for all aspects 
related to statistical design and analysis, study database development, and management and 
data reporting and sharing. A study-appointed independent Medical Safety Monitor and an 
NIH-NIDDK appointed Data and Safety Monitoring Board (DSMB) oversee safety in the 
SHARP trial. The DSMB meets every six months to review study progress and accumulated 
data. Their main responsibilities are to ensure that study participants are not exposed to 
unnecessary or unreasonable risks, and that the study is conducted with high scientific and 
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ethical standards. The DSMB is assisted by the independent safety monitor who reviews and 
adjudicates all serious adverse events throughout the study.
Study Hypothesis and Aims
The primary aim of the SHARP trial is to test the hypothesis that ERCP with miES will 
reduce the risk of a subsequent acute pancreatitis episode by 33%. This hypothesis will be 
tested by comparing the incidence of acute pancreatitis episodes that occur >30 days after 
the randomization procedure. The SHARP Steering Committee agreed that a 33% relative 
risk reduction is the minimally acceptable threshold above which the benefit of ERCP with 
miES would offset its known short- and long-term risks, including post-ERCP pancreatitis 
and post-sphincterotomy re-stenosis, respectively. Acute pancreatitis will be defined by 
consensus criteria during the baseline assessment and follow-up (Table 1).
There are several potential secondary benefits of reducing ARP episodes, which will be 
explored through secondary aims of the trial. The frequency of acute pancreatitis, defined as 
the incidence rate ratio (episodes/time pre- and post-randomization), the change in patient-
centered outcomes and progression to chronic pancreatitis and its sequelae will all be 
compared between the two treatment arms. A biological and imaging repository will be 
established for future exploratory analyses of genetic, laboratory and radiological 
associations with outcomes; the Standard Operating Procedures for the SHARP biological 
repository were derived from the ongoing Consortium for the study of Chronic Pancreatitis, 
Diabetes, and Pancreatic Cancer.10
Enrollment Criteria
Inclusion/exclusion criteria are summarized in Table 1. The possible presence of a 
pancreatic duct stricture or structural etiology for acute pancreatitis will be assessed for all 
patients during review of prior cross-sectional imaging, including magnetic resonance 
imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP). If no evidence of 
either exclusion is identified, and all other eligibility criteria are met, patients who consent to 
randomization will be scheduled for the pre-randomization EUS.
The threshold at which alcohol causes acute pancreatitis is poorly understood and patient-
dependent. Alcohol use will also be quantified using the TWEAK (Tolerance, Worry, Eye-
opener, Amnesia, and “K”-ut down) during the baseline assessment.11,12 The SHARP trial 
excludes patients with a high probability of having alcoholic pancreatitis.
Sites and Recruitment
The SHARP trial will be completed at 17 centers in the U.S., Canada, Netherlands, and U.K. 
Each center represents a regional referral center for pancreatic disorders and ERCP. The 
recruitment process will not involve any procedures that may be construed as coercive, and 
there will be no restriction to recruitment based on sociodemographic factors including age, 
gender, or ethnic characteristics. Participants will be recruited from within clinical practices. 
It is expected that the informed consent process will occur in ambulatory clinics. If a patient 
is agreeable to participate, randomization procedures will commence thereafter. In an effort 
to stimulate recruitment and raise awareness, referring physician practices will be reminded 
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of the SHARP trial through regular communications. The trial began enrollment in 
September, 2018 with a planned primary analysis to be completed in September, 2023. All 
authors had access to the study data and reviewed and approved the final manuscript.
Baseline Assessments, Randomization, and Study Procedures
In addition to assessments related to eligibility, all participants will be administered 
questionnaires and medical records will be reviewed to collect information relevant to study 
objectives (Table 2). If a participant has not been formally diagnosed, assessment for 
diabetes mellitus and exocrine insufficiency will be performed. Study participants will be 
asked to provide blood and urine samples for a study biorepository which will be processed 
within 4 hours of collection and stored at −80°C until testing.
A linear echoendoscope will be used for EUS exam. In addition to confirming the absence of 
exclusion criteria, the EUS exam will assess for pancreatic duct diameter and document 
parenchymal and ductal changes in the pancreas. Prior to randomization, the amount and 
type of intravenous fluids to be administered during the periprocedural period (irrespective 
of treatment allocation) will be documented.
Unless a definitive obstructive lesion or any other exclusion criterion is identified during 
EUS, the participant will be randomized 1:1 to either EUS + sham or EUS + ERCP with 
miES. Clinical center, pancreatic duct diameter and a dichotomized variable for number of 
acute pancreatitis episodes (1–2 vs ≥3) in the two years prior to randomization will be 
included in the randomization algorithm to ensure a balanced distribution between treatment 
arms. The SHARP trial utilizes a web-based central randomization system housed at the 
SHARP Statistical and Data Coordinating Center at the Medical University of South 
Carolina.
Participants randomized to treatment (ERCP + miES), will undergo the procedure following 
the EUS, under the same anesthetic. Indomethacin or diclofenac (100mg per rectum) will be 
administered for post-ERCP pancreatitis prophylaxis at the onset of the ERCP procedure in 
patients with no known allergy. Techniques for minor papilla cannulation will be left to the 
discretion of the treating endoscopist. Variables of interest pertaining to ERCP include the 
use of enhanced maneuvers to facilitate cannulation (e.g., intravenous secretin and mucosal 
contrast agents such as methylene blue), performance of precut sphincterotomy, extent of 
pancreatography, presence of complete vs. incomplete pancreas divisum, miES technique, 
and type of prophylactic pancreatic duct stent. This technical approach is intended to mimic 
real-life practice and maximize the study’s external validity. These variables will be tracked 
in order to determine their impact on study outcomes (Table 2). If a mucosal contrast agent 
was not used to assist in cannulation, 3 ml of dilute dye will be injected into the duodenum 
before the end of the procedure; and, a stent will be left in the duodenum if one cannot be 
placed into the pancreatic duct.
For participants assigned to the sham group, a duodenoscope will be passed to the second 
portion of the duodenum. The minor papilla will be photo documented, 3 ml of dilute dye 
such as methylene blue in US sites, or similar dye in non-US sites, will be injected into the 
duodenum, and a plastic stent will be left in the duodenum.
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Follow-up Procedures and Guidelines for Intervention
Enrolled participants will be followed for a maximum of 48 months depending on their time 
of enrollment. Scheduled in-person follow-up will occur at day 30 and month 18 (Table 2). 
These in-person visits will be directed by blinded study personnel at each site. During the 
day 30 follow-up, the participant will be assessed for adverse events and complete an 
abdominal X-ray to confirm spontaneous passage of the pancreatic duct stent. During the 
month 18 follow-up visit, participants will undergo an MRI with MRCP to assess for 
morphologic changes in the pancreas along with functional pancreas testing. All other 
follow-up visits will be completed by telephone every 6 months (scheduled) until the end of 
the study or ad hoc (if symptoms suggestive of acute pancreatitis develop). The date of 
diagnosis of acute pancreatitis as reported by the enrolling site will be used for the primary 
outcome. Investigators will make every effort to avoid ERCPs during the follow-up period 
until this outcome has been reached. The SHARP protocol provides guidance (Table 3) on 
repeat ERCPs to assist a blinded investigator who is evaluating participants during the 
follow-up period. Ultimately the decision to recommend ERCP during the follow-up period 
is based on the best clinical judgement of a blinded physician investigator evaluating the 
participant.
Maintenance of the Blind
All sites will have a minimum of two physician investigators, of which one will serve as 
blinded investigator and one as unblinded investigator for each participant. In order to 
maintain blinding of participants, healthcare providers making clinical decisions that may 
directly impact the primary endpoint, and study coordinators who will obtain outcome data, 
the endoscopy report will include language indicating the participation in a blinded research 
study in which he/she may or may not have undergone the ERCP with miES procedure. All 
facility and professional charges associated with the randomization procedure will be billed 
to the research study.
To test the effectiveness of blinding procedures, participants and blinded study personnel 
will be asked at the 30-day follow-up assessment to which group they believe the participant 
was assigned. This question will be repeated at the Month 18 visit. If the participant and/or 
assessor becomes knowledgeable of treatment assignment at any point during study 
participation, this will be documented in the study database. The participant will remain in 
the study and be part of the analysis population (intention to treat analysis).
Observational Cohort
Approximately 100 patients who meet all eligibility criteria but who decline randomization, 
decline ERCP or those in whom ERCP is not recommended by the unblinded physician will 
be invited to participate in an observational cohort study (Fig. 1). Patients who provide 
consent will be followed for subsequent acute pancreatitis episodes, systematic, semiannual 
assessments for patient-centered outcomes and clinical (observational) assessments for the 
interval development of chronic pancreatitis and exocrine or endocrine insufficiency. These 
participants will also provide biological samples at baseline for the SHARP biorepository.
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Statistical Analysis Plan and Sample Size Estimation
Natural history studies specific to pancreas divisum are lacking, but retrospective cohort 
studies and one surgical series suggest the recurrence rate following minor papilla stenting, 
miES, or surgical sphincteroplasty is 15–50%.13–15 Given the short-term risk of post-ERCP 
pancreatitis (~10%), costs of ERCP, and potential for post-sphincterotomy re-stenosis, we 
believe a minimum effect size of 33% relative risk reduction is of clinical relevance. Based 
on the limited information in the literature, we anticipate that the risk of recurrence within 
12 months of randomization is 60% in the EUS + sham arm. A 33% relative risk reduction 
would demonstrate an event rate of 40% in the miES arm. Assuming an exponential hazard 
(constant hazard), these proportions translate into median times to recurrence of 9.1 and 16.3 
months, respectively. Setting the subject accrual period to 42 months, a maximum follow-up 
period of 48 months, a 2-sided type I error of 5%, power of 85%, and non-adherence rate of 
20%, the trial requires a total sample size of 234 randomized participants (164 observed 
events). The non-adherence factor is primarily to account for the potential dilution of effect 
size due to technical failures in the miES arm, where a patient is assigned to the miES arm 
but the treating endoscopist cannot access the duct as well as the potential competing risks.
It is possible that participants will experience a pancreatitis-related event such as severe 
pain, without reaching the actual event of primary interest (acute pancreatitis). In some of 
these cases, participants may be treated with an ERCP. An ERCP for pain alone will be 
treated as a competing risk in the primary analysis. We recognize that sample size estimation 
is based on assumptions and if the assumed event rate is lower than expected, then we may 
begin to see a decrease in power. For this reason, the SHARP design includes a blinded 
sample size re-estimation plan.16,17 This information will be shared with the Data and Safety 
Monitoring Board during closed session and it will be the DSMB’s decision to recommend 
an increase in the total sample size.
The SHARP trial does not incorporate any interim analyses to stop the trial early for 
overwhelming efficacy or for futility of the primary outcome. To stop the trial early would 
lead to potentially biased estimates of the treatment effect as well as reduced data for 
interpretation of the secondary outcomes that require long term follow up. The study team 
does have in place a detailed safety monitoring plan that will allow the DSMB to examine 
safety data and provide recommendations to the NIDDK if the trial should indicate stopping 
early due to safety issues. The primary efficacy analysis will be conducted when all 
participants have completed follow up. The primary hypothesis will be tested using the 
intention-to-treat analysis population (all randomized) and a two-sided 0.05 level of 
significance with the method of Fine and Gray for modeling the hazard of the sub 
distribution in the presence of competing risks. Two variables included in the randomization 
scheme, duct diameter and number of attacks within 24 months prior to enrollment, will be 
included as covariates in the primary analysis. As an exploratory analysis of the primary, the 
model will be run with additional potential covariates/prognostic variables such as the 
presence of chronic pain at baseline, number of EUS features (parenchymal and ductal), age, 
gender, race, and presence of endocrine and exocrine insufficiency. All adverse events will 
be summarized in terms of frequency of the event, number of participants having the event, 
severity, expectedness (anticipated/unanticipated) and relatedness to the study treatment.
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The practice of ERCP with miES for patients with idiopathic ARP and pancreas divisum is 
widespread yet decades of clinical practice have failed to refute or establish its utility, 
observational research suggests a benefit, and its practice in the West is widespread. It is 
biologically plausible that pancreas divisum represents an obstructive pancreatopathy, and 
thus treating the minor papillary orifice could ameliorate acute pancreatitis episodes. 
Pancreatic duct obstruction and transient increases in intraductal pressure is a well-
recognized mechanism for acute pancreatitis.18–25 However, pancreas divisum, a congenital 
variant that is observed in roughly 10% of the population, is not unequivocally 
overrepresented in ARP patient populations. Moreover, there seems to be a clear association 
between pancreas divisum and several genetic susceptibility mutations, although the reason 
for this phenomenon is poorly understood.26,27 For example, it is suspected that mutations in 
the Cystic Fibrosis Transmembrane Receptor gene, which impairs the amount and 
composition of pancreatic fluid, will relate to the probability of ARP following miES. The 
relationship between susceptibility mutations and response to miES will be explored using 
the SHARP Biological Repository; testing for known susceptibility mutations will be 
completed as part of the post hoc primary analysis.
Justification for Primary Outcome and Importance of Blinding
A reduction in the risk of acute pancreatitis was selected as the primary outcome since this is 
the principal objective of clinicians who offer ERCP with miES in clinical practice. In 
addition, it is implausible that an intervention which fails to reduce the risk of subsequent 
acute pancreatitis will reduce the risk of other sequelae such as interval development of 
chronic pancreatitis or its associated complications. While episodes of severe acute 
pancreatitis are typically self-evident, powering a study to reduce the risk of severe acute 
pancreatitis is impractical since these episodes represent the minority of attacks experienced 
by individuals with idiopathic ARP. There also was consideration in using incidence rate 
ratio for the primary outcome. While reducing episode frequency is important, this requires 
careful adherence to the original treatment allocation for a long follow-up period. As 
participants develop episodes of acute pancreatitis during follow-up, it will be very difficult 
for clinicians to withhold interventions (including ERCP with miES) and preserve the blind.
A recognized risk of miES is the development of symptomatic post-sphincterotomy stenosis. 
While large-scale, prospective studies with discrete criteria are lacking, rates of post-
sphincterotomy stenosis are estimated to be 20% or higher.28–32 There are no objective 
definitions for post-sphincterotomy stenosis. However, symptomatic post-sphincterotomy 
stenosis is expected to result in either acute pancreatitis (primary outcome) or pancreatitis-
related pain event(s) as defined previously. Differences in these outcomes between 
participants randomized to EUS + ERCP with miES and EUS + sham will clarify whether 
the risk of post-sphincterotomy stenosis is outweighed by its benefit.
Blinding adds substantial complexity to the SHARP protocol but is critically important in 
the assessment of outcomes. For SHARP participants who contact their providers with pain 
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reminiscent of their prior pancreatitis episodes, knowledge of treatment allocation is likely 
to impact recommendations. In such a scenario, participants who knew they underwent 
miES may be less likely to seek medical attention since they received “maximal treatment” 
previously. Similarly, clinicians with knowledge of treatment allocation may have a lower 
threshold to recommend hospital evaluation or admission (eg, laboratory or radiology 
testing, emergency room evaluation) to patients assigned to the sham group. In addition to 
clinical care, patient-reported outcomes are most susceptible to bias in an unblinded study, 
and yet are of paramount importance in SHARP. Quality of life is lower among patients with 
chronic pancreatitis and ARP, yet difficult to quantify in day-to-day clinical practice. 
Abdominal pain and pain-related disability may be increasingly burdensome for some 
patients with idiopathic ARP, especially if the disease is evolving to chronic pancreatitis. 
Masking subjects and those assessing outcomes will reduce bias in the measurement of these 
important patient-reported outcomes.
Impact and Future Directions
The absence of viable medical therapies, the plausibility that improving pancreatic flow may 
improve the disease course, the available (but weak) data in support of miES, and patients’ 
“desperation” have created the perfect storm for more than three decades of endoscopic 
intervention for idiopathic ARP. The SHARP trial will prove whether or not ERCP should 
be performed for idiopathic ARP with pancreas divisum.
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Enrollment schema. ARP indicates acute recurrent pancreatitis; ERCP, endoscopic 
retrograde cholangiopancreatography; miES; minor papilla endoscopic sphincterotomy; 
EUS, endoscopic ultrasound.
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TABLE 3.
Guidelines for ERCP During the Follow-up Period
1. Two or more episodes of acute pancreatitis
2. One episode of acute pancreatitis with local complication as defined by Atlanta criteria, that warrants pancreatogram
3. One episode of acute pancreatitis plus at least one independent pancreatitis-related pain event.
4. Interval development of symptomatic pancreatic duct obstruction (main duct stricture or stone) on cross sectional imaging
5. Two or more pancreatitis-related pain events and minimum follow-up of 12 months
Pancreas. Author manuscript; available in PMC 2020 September 01.
